A practical reference on Cyclic AMP: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-14. Anything still debated is marked as such rather than presented as settled.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
== Grants == In 1985, the Society used the proceeds from the 10th International Mass Spectrometry Conference to establish 7 Beynon PhD Studentships. In 2007, the Society announced they would initiate summer studentship projects and in 2012 they announced BMSS research grants.
Reflecting on the band's hiatus in a 2011 interview, Kinney said that Staley wasn't the only one battling addiction. He was the focal point, like singers are. So they'd single him out. But the truth was, it was pretty much everybody. I definitely had my hand firmly on the wheel going off the cliff. And the reason we pulled back – you know when you stop when you have two No. 1 records, it's not really the greatest career move – but we did that because we love each other and we didn't want to die in public. And I know for a fact in my heart that if we were to continue that I wouldn't be on the phone right now talking to you. I wouldn't have made it. I just wouldn't have. After a decade of battling drug addiction, Layne Staley was found dead in his condominium on April 19, 2002. The autopsy and toxicology report revealed that he died from a mixture of heroin and cocaine, known as "speedball". The autopsy concluded that Staley died on April 5, two weeks before his body was found. Cantrell dedicated his 2002 solo album, Degradation Trip, released two months after Staley's death, to his memory. Mike Starr later claimed on Celebrity Rehab that he was the last person to see Staley alive, and admitted to feeling guilty about not calling 911 after Staley had warned him against it. "I wish I hadn't been high on benzodiazepine [that night], I wouldn't have just walked out the door," Starr said. Following Staley's death, Mike Inez joined Heart and toured and recorded with the band from 2002 through 2006.
=== Hoffman Instrumentation Supply Inc === In 2019, Hoffman Instrumentation Supply Inc was a component vendor to Edwards' US, subsidiary Edwards Vacuum LLC, and held talks about becoming exclusive supplier for some items. It was also proposed that Hoffman would construct subassemblies and complete systems, but only for Edwards. One of Hoffman's key customers enquired whether it could provide a vacuum system that would work with pumps other than Edwards'. Hoffman informed Edwards whose response was to suggest purchasing Hoffman. Information was provided about Hoffman to Edwards for due diligence, under a non disclosure agreement, in order to progress the acquisition. It included technical specifications for the pump agnostic vacuum system and Hoffman's cost structures. The parties did not agree terms to purchase Hoffman and Edwards withdrew from the process. A group of employees left Edwards to work for Hoffman and in 2020, Edwards sought an injunction against Hoffman to prevent misuse of the ex employees's trade secrets. Hoffman counter claimed Edwards used the confidential due diligence information to pitch their products to Hoffman's key customer at prices just below Hoffman's own intended level, and to demand cost reductions from suppliers to match those obtained by Hoffman.
"True alkaloids" contain nitrogen in the heterocycle and originate from amino acids. Their characteristic examples are atropine, nicotine, and morphine. This group also includes some alkaloids that besides the nitrogen heterocycle contain terpene (e.g., evonine) or peptide fragments (e.g. ergotamine). The piperidine alkaloids coniine and coniceine may be regarded as true alkaloids (rather than pseudoalkaloids: see below) although they do not originate from amino acids. "Protoalkaloids", which contain nitrogen (but not the nitrogen heterocycle) and also originate from amino acids. Examples include mescaline, adrenaline and ephedrine. Polyamine alkaloids – derivatives of putrescine, spermidine, and spermine. Peptide and cyclopeptide alkaloids. Pseudoalkaloids – alkaloid-like compounds that do not originate from amino acids. This group includes terpene-like and steroid-like alkaloids, as well as purine-like alkaloids such as caffeine, theobromine, theacrine and theophylline. Some authors classify ephedrine and cathinone as pseudoalkaloids. Those originate from the amino acid phenylalanine, but acquire their nitrogen atom not from the amino acid but through transamination. Some alkaloids do not have the carbon skeleton characteristic of their group. So, galanthamine and homoaporphines do not contain isoquinoline fragment, but are, in general, attributed to isoquinoline alkaloids. Main classes of monomeric alkaloids are listed in the table below:
Sources: en.wikipedia.org
Coating defines the biocompatibility of the therapeutic agent and its ability to travel in the body. When the agent is not biocompatible, it will quickly be excreted from the body, and there will be magnetic accumulation or off-target therapeutic effects. The use of organic or inorganic coating molecules increases the half-life of the nanocarrier by delaying its clearance by the reticuloendothelial system (RES). This delay occurs because the coating overcomes the pH, hydrophobicity, and surface charge of the magnetic nanoparticles. Additionally, coating allows molecules to covalently bind to specific molecules, such as ligands, proteins, or antibodies, which provides binding specificity to target tissues. A common structure of coating includes the core-shell structure. In this structure, metal oxide cores are coated with biocompatible materials which allows for increased control and biocompatibility. The most common coatings used for optimum response involve the use of polysaccharides like dextran and polymers like polyethylene glycol. Furthermore, carbon coatings have proved to be biocompatible and have high capacity for absorption into cells. Even polyaniline with anti-cancer agent epirubicin can be used for tumor exploration of the brain. Polyethyleneimine has displayed high cellular accumulation and low toxicity. This coating was found to have poor pharmacokinetic properties when used alone, but with magnetic field induction, it was found to accumulate on tumors at clinically significant rates.
Silicon single crystals may be produced today in commercial facilities with extremely high purity and with few lattice defects. This method defined the Avogadro constant as the ratio of the molar volume, Vm, to the atomic volume Vatom:
In Indonesia, the hardline anti-communist General Suharto wrested control from predecessor Sukarno in an attempt to establish a "New Order". From 1965 to 1966, with the aid of the US and other Western governments, the military led the mass killing of more than 500,000 members and sympathizers of the Indonesian Communist Party and other leftist organizations, and detained hundreds of thousands in prison camps under inhumane conditions. A top-secret CIA report stated that the massacres "rank as one of the worst mass murders of the 20th century, along with the Soviet purges of the 1930s, the Nazi mass murders during the Second World War, and the Maoist bloodbath of the early 1950s." These killings served US interests and constitute a major turning point in the Cold War as the balance of power shifted in Southeast Asia.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.